RxDoctor Payments Data

Kenneth Martinez, MD

Neurology · Aliso Viejo, CANPI 1093825259

Payments from drug & device makers

$425,871in general payments, 2019–2025

Across 2,382 payments — averaging $178.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$203K
  • Merz Pharmaceuticals, LLC$95K
  • Medtronic$51K
  • Amgen$18K
  • Biohaven Pharmaceuticals, Inc.$8K
  • Boston Scientific$6K
  • plus $43K from 54 others

What the payments were for

  • Consulting fees$114,32834%
  • Speaking & faculty fees$161,70748%
  • Travel & lodging$11,0613%
  • Food & beverage$48,93615%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)534$203,095
Merz Pharmaceuticals, LLC112$95,062
Medtronic(2 entities)70$50,860
Amgen(2 entities)60$17,652
Biohaven Pharmaceuticals, Inc.25$8,309
Boston Scientific51$6,197
Merz North America, Inc.17$4,182
Teva Pharmaceuticals USA, Inc.146$4,034
Abbott44$3,097
Biohaven Pharmaceutical Holding Company Ltd.15$2,936
Janssen Global Services, LLC3$2,861
Neurocrine Biosciences, Inc.136$2,835
UCB, Inc.89$2,189
AstraZeneca80$1,849
SK Life Science, Inc.73$1,522
Lilly USA, LLC65$1,235
Jazz Pharmaceuticals Inc.73$1,024
Pfizer47$902
Kyowa Kirin, Inc.27$876
Amneal Pharmaceuticals LLC54$836
CSL Behring40$835
Lundbeck LLC42$831
Takeda Pharmaceuticals U.S.A., Inc.41$801
Eisai Inc.36$786
Acadia Pharmaceuticals Inc28$643
MDD US Operations, LLC33$606
Upsher-smith Laboratories LLC28$586
Argenx US, Inc.20$579
Adamas Pharmaceuticals, Inc.33$531
Avanir Pharmaceuticals, Inc.20$407
Biogen19$398
Acorda Therapeutics, Inc19$371
Sunovion Pharmaceuticals Inc.20$343
Supernus Pharmaceuticals, Inc.17$336
Neuropace, Inc.7$328
Ipsen Biopharmaceuticals, Inc12$316
Neurelis, Inc.18$302
Avadel CNS Pharmaceuticals, LLC8$276
Alnylam Pharmaceuticals Inc.11$268
Axsome Therapeutics, Inc.8$228
Revance Therapeutics, Inc.5$228
Avion Pharmaceuticals13$226
Tanabe Pharma America, Inc.11$224
GE HealthCare12$223
Otsuka America Pharmaceutical, Inc.9$217
Harmony Biosciences LLC8$214
Nevro Corp.4$208
Scilex Pharmaceuticals Inc.10$183
Catalyst Pharmaceuticals, Inc.8$182
Azurity Pharmaceuticals, Inc.8$156
Johnson & Johnson7$156
Averitas Pharma Inc.6$152
Corium, LLC6$148
Novartis11$141
Insightec,inc2$135
Microtransponder, Inc.4$132
Arbor Pharmaceuticals, Inc.7$113
Janssen Scientific Affairs, LLC2$101
Livanova USA, Inc.2$99
Akcea Therapeutics, Inc.4$96

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$425,871 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$2,335,045
Medicare patients
1,104
Services billed
199,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine26$479,476
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5040$385,461
IngrezzaValbenazine Tosylate17$195,810
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$95,619
GammakedImmune Globul G/Gly/Iga Avg 4612$90,160
RytaryCarbidopa/Levodopa86$84,622
NuplazidPimavanserin Tartrate15$73,523
BotoxOnabotulinumtoxina45$70,790
Nurtec OdtRimegepant Sulfate22$51,502
Emgality PenGalcanezumab-Gnlm50$44,164
Aimovig AutoinjectorErenumab-Aooe36$26,926
Ajovy SyringeFremanezumab-Vfrm24$22,943
VimpatLacosamide18$22,528
NuedextaDextromethorphan Hbr/Quinidine14$20,394
UbrelvyUbrogepant14$18,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$902$530,97848 claims
Neurocrine Biosciences, Inc.Ingrezza$2,835$195,81017 claims
AbbVieBotox, Ubrelvy$203,095$89,31659 claims
Amneal Pharmaceuticals LLCRytary$836$84,62286 claims
Acadia Pharmaceuticals IncNuplazid$643$73,52315 claims
UCB, Inc.Vimpat$2,189$22,52818 claims
Avanir Pharmaceuticals, Inc.Nuedexta$407$20,39414 claims
Upsher-smith Laboratories LLCTopiramate$586$72712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Aliso Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →